Skip to main content
SpringerLink
Log in

Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Autism and related pervasive developmental disorders (PDD) are characterized by impairments in social interaction and communication, restricted interests, and repetitive and stereotyped patterns of behavior. Individuals with PDD frequently display irritability and disruptive behaviors including tantrums, self-injurious behavior, and aggression. Atypical antipsychotics are currently the most efficacious pharmacological interventions available for treatment of irritability associated with PDD.

Objectives

This article aims to review the body of literature pertaining to the use of atypical antipsychotics in the treatment of patients with PDD.

Methods

A PubMed literature search was conducted using the following key words: autism, pervasive developmental disorders, atypical antipsychotics, risperidone, aripiprazole, quetiapine, ziprasidone, olanzapine, clozapine, paliperidone, iloperidone, asenapine, and lurasidone. Search terms were limited to English language, human subjects, and publication from 1999 to present. Relevant references from identified articles were also reviewed.

Results

The efficacy and tolerability of risperidone and aripiprazole for the treatment of irritability in autism have been established with multi-site, randomized, controlled trials. Studies supporting the use of other atypical antipsychotics are either limited in scope or less robust in their findings, though newer agents such as ziprasidone and paliperidone show promise.

Conclusions

Atypical antipsychotics are currently first-line pharmacological agents for the treatment of irritability and associated behaviors in children with PDD. Further placebo-controlled studies are warranted to characterize the efficacy and tolerability of the majority of these medications. There is also a need for the development of novel, targeted drugs with more favorable long-term side effect profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adoles Psychopharmacol 15:869–884

    Article  Google Scholar 

  • Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48:1143–1154

    Article  PubMed  Google Scholar 

  • Aman MG, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R (2010) Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adoles Psychopharmacol 20:415–422

    Article  Google Scholar 

  • American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, Text revision. American Psychiatric Association, Washington

    Google Scholar 

  • Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195–1202

    CAS  PubMed  Google Scholar 

  • Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J (1989) The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227–239

    Article  CAS  PubMed  Google Scholar 

  • Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B (2007) Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545–550

    Article  CAS  PubMed  Google Scholar 

  • Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S, DiSilvestro R, McDougle CJ, McCracken J, Vitiello B, Aman MG, Scahill L, Posey DJ, Swiezy NB (2010) Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adoles Psychopharmacol 20:83–93

    Article  Google Scholar 

  • Blair J, Scahill L, State M, Martin A (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44:73–79

    Article  PubMed  Google Scholar 

  • Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835–843

    Article  CAS  PubMed  Google Scholar 

  • CenterWatch (2012) Drug Information: FDA-Approved Drugs. http://www.centerwatch.com/drug-information/fda-approvals/. Accessed 15 Nov 2012

  • Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C (2001) Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 62:479–480

    Article  CAS  PubMed  Google Scholar 

  • Cohen SA, Fitzgerald BJ, Khan SR, Khan A (2004) The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 65:110–113

    Article  CAS  PubMed  Google Scholar 

  • Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ (2004) A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531–1536

    Article  CAS  PubMed  Google Scholar 

  • Duggal HS (2007) Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. J Child Adoles Psychopharmacol 17:261–263

    Article  Google Scholar 

  • Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurother J Am Soc Exp Neurother 7:258–263

    Article  CAS  Google Scholar 

  • Fido A, Al-Saad S (2008) Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract Int Journal Kuwait Univ Heal Sci Cent 17:415–418

    Google Scholar 

  • Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL (2004) Quetiapine in nine youths with autistic disorder. J Child Adoles Psychopharmacol 14:287–294

    Article  Google Scholar 

  • Fombonne E (2009) Epidemiology of pervasive developmental disorders. Pediatr Res 65:591–598

    Article  PubMed  Google Scholar 

  • Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E (2008) Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry 17:217–225

    Article  PubMed  Google Scholar 

  • Gobbi G, Pulvirenti L (2001) Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci JPN 26:340–341

    CAS  Google Scholar 

  • Goforth HW, Rao MS (2003) Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatr 37:775–776

    Article  Google Scholar 

  • Golubchik P, Sever J, Weizman A (2011) Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 34:216–219

    Article  CAS  PubMed  Google Scholar 

  • Hardan AY, Jou RJ, Handen BL (2005) Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35:387–391

    Article  PubMed  Google Scholar 

  • Ho JG, Caldwell RL, McDougle CJ, Orsagh-Yentis DK, Erickson CA, Posey DJ, Stigler KA (2012) The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adoles Psychopharmacol 22:277–283

    Article  Google Scholar 

  • Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adoles Psychopharmacol 16:541–548

    Article  Google Scholar 

  • Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22:455–460

    Article  CAS  PubMed  Google Scholar 

  • Lambrey S, Falissard B, Martin-Barrero M, Bonnefoy C, Quilici G, Rosier A, Guillin O (2010) Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adoles Psychopharmacol 20:79–80

    Article  Google Scholar 

  • Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001) Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40:887–894

    Article  CAS  PubMed  Google Scholar 

  • Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140–147

    Article  PubMed  Google Scholar 

  • Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adoles Psychopharmacol 17:779–790

    Article  Google Scholar 

  • Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110–1119

    Article  PubMed  Google Scholar 

  • Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL (2011) Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 72:1270–1276

    Article  CAS  PubMed  Google Scholar 

  • Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adoles Psychopharmacol 9:99–107

    Article  CAS  Google Scholar 

  • Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125–1127

    Article  PubMed  Google Scholar 

  • Masi G, Cosenza A, Mucci M, Brovedani P (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206–1214

    Article  CAS  PubMed  Google Scholar 

  • McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Kem DL, Posey DJ (2002) Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921–927

    Article  PubMed  Google Scholar 

  • McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142–1148

    Article  PubMed  Google Scholar 

  • McDougle CJ, Stigler KA, Erickson CA, Posey DJ (2008) Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69(Suppl 4):15–20

    CAS  PubMed  Google Scholar 

  • McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127:e1312–e1321

    Article  PubMed  Google Scholar 

  • Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E (2008) Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 17:1–8

    Article  PubMed  Google Scholar 

  • Nagaraj R, Singhi P, Malhi P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21:450–455

    PubMed  Google Scholar 

  • Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540

    Article  PubMed  Google Scholar 

  • Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F (2007) Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 37:367–373

    Article  PubMed  Google Scholar 

  • Posey DJ SK, Erickson CA, McDougle CJ (2007) Treatment of autism with antipsychotics. In: Hollander EAE (ed) Clinical manual for the treatment of autism. American Psychiatric Publishing, Washington

    Google Scholar 

  • Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37–44

    Article  CAS  PubMed  Google Scholar 

  • Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361–1369

    Article  Google Scholar 

  • Rosenbaum JFAG, Hyman SE, Labbate LA, Fava M (eds) (2005) Handbook of psychiatric drug therapy, 5th edn. Lippincott Williams and Wilkins, Philadelphia

    Google Scholar 

  • Roser P, Haussleiter IS, Juckel G, Brune M (2009) Paliperidone in an adult patient with Asperger syndrome: case report. Pharmacopsychiatry 42:78–79

    Article  CAS  PubMed  Google Scholar 

  • Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634–e641

    Article  PubMed  Google Scholar 

  • Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adoles Psychopharmacol 14:455–463

    Article  Google Scholar 

  • Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adoles Psychopharmacol 19:265–274

    Article  Google Scholar 

  • Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ (2010) Paliperidone for irritability in autistic disorder. J Child Adoles Psychopharmacol 20:75–78

    Article  Google Scholar 

  • Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ (2012) Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology 223:237–245

    Article  CAS  PubMed  Google Scholar 

  • Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137–1144

    Article  PubMed  Google Scholar 

  • Valicenti-McDermott MR, Demb H (2006) Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adoles Psychopharmacol 16:549–560

    Article  Google Scholar 

  • Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C (1996) Clinical effects of clozapine on autistic disorder. Am J Psychiatry 153:738

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors do not have any conflicts of interest or financial disclosures to report.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, MassGeneral Hospital for Children, Harvard Medical School, Lexington, MA, 02421, USA

    Laura C. Politte & Christopher J. McDougle

  2. Harvard Medical School, Boston, MA, USA

    Laura C. Politte & Christopher J. McDougle

Authors
  1. Laura C. Politte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. McDougle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura C. Politte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Politte, L.C., McDougle, C.J. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology 231, 1023–1036 (2014). https://doi.org/10.1007/s00213-013-3068-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-013-3068-y

Keywords

Search

Navigation